{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T01:45:48Z","timestamp":1767923148851,"version":"3.49.0"},"reference-count":21,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T00:00:00Z","timestamp":1559088000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0626-9","type":"journal-article","created":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T13:02:58Z","timestamp":1559134978000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?"],"prefix":"10.1136","volume":"7","author":[{"given":"Anne","family":"Zaremba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleftheria","family":"Chorti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Finja","family":"Jockenh\u00f6fer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saskia","family":"Bolz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selma","family":"Sirin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Glas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen C.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selma","family":"Ugurel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Roesch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Livingstone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Hagenacker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,5,29]]},"reference":[{"key":"626_CR1","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","volume":"82","author":"D Makarious","year":"2017","unstructured":"Makarious D, Horwood K, Coward JIG, et al. Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur J Cancer. 2017;82:128\u201336.","journal-title":"Eur J Cancer"},{"issue":"2","key":"626_CR2","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","volume":"28","author":"AM Menzies","year":"2017","unstructured":"Menzies AM, Johnson DB, Ramanujam S, et al. Anti PD therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017;28(2):368\u201376.","journal-title":"Ann Oncol"},{"key":"626_CR3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ejca.2016.12.038","volume":"75","author":"R Gutzmer","year":"2017","unstructured":"Gutzmer R, Koop A, Meier F, et al. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. Eur J Cancer. 2017;75:24\u201332.","journal-title":"Eur J Cancer"},{"issue":"9","key":"626_CR4","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1002\/cam4.815","volume":"5","author":"JG Iyer","year":"2016","unstructured":"Iyer JG, Blom A, Doumani R, et al. Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma. Cancer Med. 2016;5(9):2294\u2013301.","journal-title":"Cancer Med"},{"key":"626_CR5","doi-asserted-by":"publisher","first-page":"17077","DOI":"10.1038\/nrdp.2017.77","volume":"3","author":"JC Becker","year":"2017","unstructured":"Becker JC, Stang A, Nghiem P, et al. Merkel cell carcinoma. Nat Rev Dis Primers. 2017;3:17077.","journal-title":"Nat Rev Dis Primers"},{"issue":"26","key":"626_CR6","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","volume":"374","author":"PT Nghiem","year":"2016","unstructured":"Nghiem PT, Bhatia S, Lipson EJ, et al. PD-1 blockade with Pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med. 2016;374(26):2542\u201352.","journal-title":"N Engl J Med"},{"issue":"10","key":"626_CR7","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","volume":"17","author":"HL Kaufman","year":"2016","unstructured":"Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17(10):1374\u201385.","journal-title":"Lancet Oncol"},{"key":"626_CR8","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","volume":"60","author":"L Zimmer","year":"2016","unstructured":"Zimmer L, Goldinger SM, Hofmann L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:210\u201325.","journal-title":"Eur J Cancer"},{"issue":"6","key":"626_CR9","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1097\/WCO.0000000000000503","volume":"30","author":"M Touat","year":"2017","unstructured":"Touat M, Talmasov D, Psimaras D, et al. Neurological toxicities associated with immune-checkpoint inhibitors. Curr Opin Neurol. 2017;30(6):659\u201368.","journal-title":"Curr Opin Neurol"},{"key":"626_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","volume":"73","author":"S Cuzzubbo","year":"2017","unstructured":"Cuzzubbo S, Javeri F, Tissier M, et al. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer. 2017;73:1\u20138.","journal-title":"Eur J Cancer"},{"issue":"2","key":"626_CR11","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","volume":"2","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Sullivan RJ, Clark JI, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2016;2(2):234\u201340.","journal-title":"JAMA Oncol"},{"issue":"3","key":"626_CR12","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/ene.12329","volume":"21","author":"EG Pedersen","year":"2014","unstructured":"Pedersen EG, Potteg\u00e5rd A, Gaist D, et al. Risk of non-melanoma skin cancer in myasthenia patients treated with azathioprine. Eur J Neurol. 2014;21(3):454\u20138.","journal-title":"Eur J Neurol"},{"issue":"7","key":"626_CR13","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.healun.2018.03.012","volume":"37","author":"M Vos","year":"2018","unstructured":"Vos M, Plasmeijer EI, R\u00e1cz E, et al. Azathioprine to mycophenolate mofetil transition and risk of squamous cell carcinoma after lung transplantation. J Heart Lung Transplant. 2018;37(7):853\u20139.","journal-title":"J Heart Lung Transplant"},{"issue":"6","key":"626_CR14","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/ene.12108","volume":"20","author":"EG Pedersen","year":"2013","unstructured":"Pedersen EG, Potteg\u00e5rd A, Gaist D, et al. Use of azathioprine for non-thymoma myasthenia and risk of cancer: a nationwide case-control study in Denmark. Eur J Neurol. 2013;20(6):942\u20138.","journal-title":"Eur J Neurol"},{"issue":"4","key":"626_CR15","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/ijd.13409","volume":"56","author":"HC Perez","year":"2017","unstructured":"Perez HC, Benavides X, Lozano E, et al. Basic aspects of the pathogenesis and prevention of non-melanoma skin cancer in solid organ transplant recipients: a review. Int J Dermatol. 2017;56(4):370\u20138.","journal-title":"Int J Dermatol"},{"issue":"4","key":"626_CR16","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"626_CR17","doi-asserted-by":"publisher","first-page":"E120","DOI":"10.1002\/mus.26021","volume":"57","author":"DE Earl","year":"2018","unstructured":"Earl DE, Loochtan AI, Bedlack RS. Refractory myasthenia gravis exacerbation triggered By pembrolizumab. Muscle Nerve. 2018;57(4):E120\u20131.","journal-title":"Muscle Nerve"},{"issue":"2","key":"626_CR18","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3233\/JND-170219","volume":"4","author":"DS Cooper","year":"2017","unstructured":"Cooper DS, Meriggioli MN, Malik R, et al. Severe Exacerbation of Myasthenia Gravis Associated with Checkpoint Inhibitor Immunotherapy. J Neuromuscul Dis. 2017;4(2):169\u201373.","journal-title":"J Neuromuscul Dis"},{"issue":"28","key":"626_CR19","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","volume":"36","author":"KC Arbour","year":"2018","unstructured":"Arbour KC, Mezquita L, Hellmann MD, et al. Impact of baseline steroids on efficacy of programmed cell Death-1 and programmed death-ligand 1 blockade in patients with non\u2013small-cell lung Cancer. J Clin Oncol. 2018;36(28):2872\u20138.","journal-title":"J Clin Oncol"},{"key":"626_CR20","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3389\/fonc.2018.00310","volume":"8","author":"MD Forster","year":"2018","unstructured":"Forster MD, Devlin MJ. Immune checkpoint inhibition in head and neck Cancer. Front Oncol. 2018;8:310.","journal-title":"Front Oncol"},{"issue":"10088","key":"626_CR21","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Melero I, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492\u2013502.","journal-title":"Lancet"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0626-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0626-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0626-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T03:10:37Z","timestamp":1608088237000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0626-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,29]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["626"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0626-9","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,29]]},"assertion":[{"value":"29 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"A. Zaremba received travel support from Novartis and Bristol-Myers Squibb.E. Chorti received travel support from Bristol-Myers Squibb, MSD SHARP & DOHME and Novartis.F. Jockenh\u00f6fer declares that she has no conflicts of interest.S. Bolz declares that she has no conflicts of interest.S. Sirin declares that she has no conflicts of interest.M. Glas reports a Consulting \/ advisory role to Roche, Novartis, Daiichi Sankyo, Novocure and travel support from Medac and Novocure. Furthermore he received Honoraria from Novartis, Merck, Novocure, Medac, and Kyowa Kirin.J.C.Becker has received speaker honoraria from Amgen, MerckSerono, Pfizer, and Sanofi; he has received advisory board honoraria from Amgen, CureVac, eTheRNA, Laser, Analytica, Lytix, MerckSerono, Novartis, Rigontec, Takeda and Sanofi; and he has received research funding from Alcedis, Amgen, Boehringer Ingelheim, BMS and MerckSerono. J.C.Becker\u2019s activities with Bristol-Myers Squibb, MerckSerono and Pfizer are related to the submitted report (therapy of advanced MCC).S. Ugurel declares advisory board and speakers honoraria from Bristol-Myers-Squibb, Merck Sharp& Dohme and Roche, as well as grant and travel support from Bristol-Myers-Squibb, Merck Sharp & Dohme, Roche und medac.A. Roesch reports non-financial support from Amgen, non-financial support from Roche, non-financial support and personal fees from Merck\/MSD, non-financial support and grants from Novartis, non-financial support and grants from BMS, non-financial support from TEVA and grants from Adtec.D. Schadendorf reports personal fees, adboards and patient\u2019s fees from Pierre Fabre, personal fees from Amgen, personal fees from Boehringer Ingelheim, personal fees from Leo Pharma, personal fees and patients\u2019 fees from Roche, personal fees and patients\u2019 fees from MSD, personal fees from Incyte, personal fees and patients\u2019 fees from Regeneron, personal fees from 4SC, personal fees from AstraZeneca, grants, personal fees and patients\u2019 fees from BMS, personal fees and patients\u2019 fees from Merck-EMD, personal fees from Pfizer, personal fees and patients\u2019 fees from Philiogen, and personal fees from Array.E. Livingstone has had intermittent advisory board relationships with Roche, BMS, Novartis and Actelion and has received travel grants and honoraria from Roche, BMS, MSD, Amgen, Novartis, Boehringer-Ingelheim, medac.T. Hagenacker has received honoraria and travel reimbursement from Alexion, CSL Behring, Novartis, Biogen, Pfizer.L. Zimmer has served as consultant or\/and has received honoraria from Roche, Bristol-Myers Squibb (BMS), Merck Sharp& Dohme (MSD), Novartis, Merck, Sanofi, Pierre Fabre and travel support from MSD, BMS, Amgen, Pierre Fabre and Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"141"}}